A Phase 1 interventional study of Denosumab and Midazolam in Postmenopausal Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-08-07.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 29th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 1, and was the 10th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Lambda Therapeutic Research Ltd. · Sites in India
Ages 55–90 · Women only
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 45 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 278 across the 31 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 31 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 20th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2010, is the only one in phase 1, and was the 11th registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing denosumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, drug-drug interaction study in postmenopausal women with osteoporosis.
Approximately 27 subjects (Group A: 18; Group B: 9) will receive a 2 mg oral dose of midazolam on day 1 followed by a 24 hour PK collection. Subjects randomized to Group A will receive a single 60 mg subcutaneous (SC) dose of denosumab on day 2 administered in the abdomen. On study day 16, another 2 mg oral dose of midazolam will be administered to all subjects (Groups A and B) followed by a 24 hour PK collection. The primary analysis to determine the effect of denosumab on the PK of midazolam will be based on data from subjects in Group A only.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All 27 subjects will receive midazolam.
Drug: Denosumab
Eighteen (18) subjects will receive denosumab.
Drug: Midazolam
Ratio of Pharmcokinetic (PK) Area Under the Concentration Time Curve (AUC) Parameter Estimates Between Day 16 (Midazolam With the Presence of Denosumab) and Day 1 (Midazolam Only)
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
Time frame: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
Estimates of Inter- and Intra-subject Variability for the PK AUC Parameters for Midazolam With Denosumab Group
AUC Subject denotes the inter-subject variability, while AUC Residual denotes the intra-subject variability
Time frame: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
Estimates of Inter- and Intra-subject Variability for PK Maximum Observed Plasma Concentration (Cmax) Parameter for Midazolam With Denosumab Group
Cmax Subject denotes the inter-subject variability, while Cmax Residual denotes the intra-subject variability
Time frame: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
Ratio of PK Cmax Parameter Estimates Between Day 16 (Midazolam With the Presence of Denosumab) and Day 1 (Midazolam Only)
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
Time frame: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
Ratio of PK AUC Parameter Estimates Between Day 16 (Midazolam Only) and Day 1(Midazolam Only)
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
Time frame: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
Estimates of Inter- and Intra-subject Variability for the PK AUC Parameters for Midazolam Only Group
AUC Subject denotes the inter-subject variability, while AUC Residual denotes the intra-subject variability.
Time frame: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
Estimates of Inter- and Intra-subject Variability for PK Cmax Parameter for Midazolam Only Group
Cmax Subject denotes the inter-subject variability, while Cmax Residual denotes the intra-subject variability.
Time frame: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
Summary of Serum Denosumab Concentration
This table summarizes serum Denosumab for Midazolam with Denosumab group. The Lower Limit Of Quantification (LLOQ) is 20 ng/mL. On Day 2 (pre-dose), the true value is below LLOQ, and is treated as 0 in the analysis.
Time frame: Baseline (day 2 pre-dose) to day 16
Summary of Serum C-Telopeptide Concentration
This table summarizes serum C-Telopeptide (sCTX) concentration raw values for Midazolam with Denosumab group.
Time frame: Baseline (day 2 pre-dose) to day 16
Summary of Percent Change From Baseline to Day 16 for Serum C-Telopeptide Concentration
This table summarizes percent change from baseline to day 16 for serum C-Telopeptide (sCTX) concentration raw values for Midazolam with Denosumab group.
Time frame: Baseline (day 2 pre-dose) to day 16
Ratio of PK Cmax Parameter Estimates Between Day 16 (Midazolam Only) and Day 1(Midazolam Only)
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
Time frame: From day 1 pre-dose to 24 hours post-dose and from day 16 pre-dose to 24 hours post-dose
| Milestone | Midazolam With Denosumab | Midazolam Only |
|---|---|---|
| Started | 21 | 9 |
| Treated | 19 | 8 |
| Completed | 18 | 8 |
| Not completed | 3 | 1 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
| unitless | Midazolam With Denosumab |
|---|---|
| AUC (0-t) | 1.10 (0.94 to 1.29) |
| AUC (0-inf) | 1.12 (0.95 to 1.31) |
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
| unitless | Midazolam Only |
|---|---|
| AUC (0-t) | 0.98 (0.83 to 1.15) |
| AUC (0-inf) | 0.98 (0.84 to 1.15) |
AUC Subject denotes the inter-subject variability, while AUC Residual denotes the intra-subject variability
| ng*hr/mL | Midazolam With Denosumab |
|---|---|
| AUC (0-t) Subject: Inter-subject | 0.19 ± 0.079 |
| AUC (0-t) Residual: Intra-subject | 0.07 ± 0.025 |
| AUC (0-inf) Subject: Inter-subject | 0.21 ± 0.085 |
| AUC (0-inf) Residual: Intra-subject | 0.08 ± 0.027 |
Cmax Subject denotes the inter-subject variability, while Cmax Residual denotes the intra-subject variability
| ng/mL | Midazolam With Denosumab |
|---|---|
| Cmax Subject: Inter-subject | 0.15 ± 0.064 |
| Cmax Residual: Intra-subject | 0.07 ± 0.023 |
AUC Subject denotes the inter-subject variability, while AUC Residual denotes the intra-subject variability.
| ng*hr/mL | Midazolam Only |
|---|---|
| AUC (0-t) Subject: Inter-subject | 0.27 ± 0.155 |
| AUC (0-t) Residual: Intra-subject | 0.03 ± 0.016 |
| AUC (0-inf) Subject: Inter-subject | 0.31 ± 0.175 |
| AUC (0-inf) Residual: Intra-subject | 0.03 ± 0.015 |
Cmax Subject denotes the inter-subject variability, while Cmax Residual denotes the intra-subject variability.
| ng/mL | Midazolam Only |
|---|---|
| Cmax Subject: Inter-subject | 0.23 ± 0.143 |
| Cmax Residual: Intra-subject | 0.06 ± 0.035 |
This table summarizes serum Denosumab for Midazolam with Denosumab group. The Lower Limit Of Quantification (LLOQ) is 20 ng/mL. On Day 2 (pre-dose), the true value is below LLOQ, and is treated as 0 in the analysis.
| ng/mL | Midazolam With Denosumab |
|---|---|
| Day 2 (Pre-dose) | 0 ± NA |
| Day 16 (0hr) | 5820 ± 1800 |
| Day 17 (24hr) | 5500 ± 1940 |
This table summarizes serum C-Telopeptide (sCTX) concentration raw values for Midazolam with Denosumab group.
| ng/mL | Midazolam With Denosumab |
|---|---|
| Baseline (day 2 pre-dose) | 0.4655 ± 0.0698 |
| Day 16 | 0.0606 ± 0.0030 |
| Change from baseline to Day 16 | -0.4079 ± 0.0702 |
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
| unitless | Midazolam With Denosumab |
|---|---|
| Ratio of PK Cmax Parameter Estimates Between Day 16 (Midazolam With the Presence of Denosumab) and Day 1 (Midazolam Only) | 1.11 (0.96 to 1.29) |
This table summarizes percent change from baseline to day 16 for serum C-Telopeptide (sCTX) concentration raw values for Midazolam with Denosumab group.
| percentage | Midazolam With Denosumab |
|---|---|
| Summary of Percent Change From Baseline to Day 16 for Serum C-Telopeptide Concentration | -87.52 (-91.45 to -80.01) |
The ratio and confidence interval are calculated based on natural log scale data and converted back to the original scale.
| unitless | Midazolam Only |
|---|---|
| Ratio of PK Cmax Parameter Estimates Between Day 16 (Midazolam Only) and Day 1(Midazolam Only) | 1.05 (0.82 to 1.33) |
Collected over 47 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Midazolam With Denosumab Group With Midazolam 2mg on Day 1 | — | 0/19 (0%) | 9/19 (47.4%) |
| Midazolam With Denosumab Group With Denosumab 60mg on Day 2-15 | — | 0/18 (0%) | 6/18 (33.3%) |
| Midazolam With Denosumab Group With Midazolam 2mg on Day 16 | — | 0/18 (0%) | 10/18 (55.6%) |
| Midazolam Only Group With Midazolam 2mg on Day 1 | — | 0/8 (0%) | 2/8 (25%) |
| Midazolam Only Group With Midazolam 2mg on Day 2-15 | — | 0/8 (0%) | 1/8 (12.5%) |
| Midazolam Only Group With Midazolam 2mg on Day 16 | — | 0/8 (0%) | 1/8 (12.5%) |
| Event | Midazolam With Denosumab Group With Midazolam 2mg on Day 1 | Midazolam With Denosumab Group With Denosumab 60mg on Day 2-15 | Midazolam With Denosumab Group With Midazolam 2mg on Day 16 | Midazolam Only Group With Midazolam 2mg on Day 1 | Midazolam Only Group With Midazolam 2mg on Day 2-15 | Midazolam Only Group With Midazolam 2mg on Day 16 |
|---|---|---|---|---|---|---|
| SomnolenceNervous system disorders | 7/19 | 0/18 | 7/18 | 2/8 | 0/8 | 0/8 |
| HeadacheNervous system disorders | 1/19 | 0/18 | 3/18 | 1/8 | 0/8 | 0/8 |
| ConstipationGastrointestinal disorders | 0/19 | 1/18 | 0/18 | 0/8 | 1/8 | 0/8 |
| DizzinessNervous system disorders | 1/19 | 0/18 | 2/18 | 0/8 | 0/8 | 1/8 |
| Injection site painGeneral disorders | 0/19 | 2/18 | 0/18 | 0/8 | 0/8 | 0/8 |
| NauseaGastrointestinal disorders | 1/19 | 1/18 | 1/18 | 0/8 | 0/8 | 0/8 |
| ChillsGeneral disorders | 0/19 | 1/18 | 0/18 | 0/8 | 0/8 | 0/8 |
| NasopharyngitisInfections and infestations | 0/19 | 0/18 | 1/18 | 0/8 | 0/8 | 0/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/19 | 1/18 | 0/18 | 0/8 | 0/8 | 0/8 |
| Neck painMusculoskeletal and connective tissue disorders | 0/19 | 0/18 | 1/18 | 0/8 | 0/8 | 0/8 |
| Age, Continuous(years) | Midazolam With Denosumab | Midazolam Only | Total |
|---|---|---|---|
| Mean | 64.42 ± 6.16 | 66.25 ± 5.34 | 64.96 ± 5.89 |
| Age, Customized(Participants) | Midazolam With Denosumab | Midazolam Only | Total |
|---|---|---|---|
| <65 years | 7 | 3 | 10 |
| >=65 years and <75 years | 12 | 4 | 16 |
| >=75 years | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | Midazolam With Denosumab | Midazolam Only | Total |
|---|---|---|---|
| Female | 19 | 8 | 27 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Midazolam With Denosumab | Midazolam Only | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 4 | 11 |
| Not Hispanic or Latino | 12 | 4 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Midazolam With Denosumab | Midazolam Only | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 17 | 6 | 23 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
No study locations are listed for this record.
The record gives a start of Nov 2010, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Denosumab · Midazolam
Osteoporosis, Postmenopausal →